ASKP3 - 2022 Fifth Year Anniversary Conference

Thursday, June 09 2022 1:00 PM - Saturday, June 11 2022 5:00 PM [CDT]

101, Red River Street, Austin, TX, 78701, United States

Register Now

1. Select Seats

2. Review and Proceed

Days
Hours
Minutes
Seconds

Registration

Sale ended

Thursday Introductory Ketamine Lectures Partial Approval - $300.00

This is a series of 4 lectures on introductory topics that is intended for the provider just starting or with limited experience. The lectures will be given by the ASKP3 Executive Committee (Sandhya Prashad, MD, Lisa Harding, MD, Steven Mandel, MD and Erin Amato, MD) and will also have an extensive Q&A component. Space is limited.

sales ended

Regular Registration Partial Approval - $895.00

Sale ended

Late Registration Partial Approval - $999.00

Enter your discount code

  • Subtotal (excluding fees and discounts)
  • Fee
  • Total amount

Thursday, June 09 2022 1:00 PM - Saturday, June 11 2022 5:00 PM [CDT]

Fairmont Austin Hotel, 101, Austin, TX, 78701, United States.

This is the Fifth Year Anniversary Conference for the American Society of Ketamine Physicians, Psychotherapists & Practitioners.  A conference involving multi-disciplinary speakers discussing ketamine use for mood disorders, psychotherapy and pain conditions.   Please join us for this educational conference and extraordinary networking experience. 

 

We heard your interests in our survey and we are answering the call.

  • Access to high quality data
  • Best practice policies
  • Facetime with experts in the field
  • Networking Opportunities

 

We are excited to celebrate our 5th year back where it all started in Austin, Texas.

 

AMERICAN SOCIETY OF KETAMINE PHYSICIANS, PSYCHOTHERAPISTS & PRACTITIONERS

 5TH ANNUAL CONFERENCE

June 9th - June 11th

 

 

Hotel Accomodations

A limited number of rooms is available. Ask for the "ASKP3" room block rate of $239 (plus taxes). The cut-off date for room reservations is Thursday, May 19, or earlier if the blocks sell out. Act early to ensure room and rate availability.

Fairmont Austin Hotel
(512) 600-2000
Booking link: https://book.passkey.com/e/50300187

Hilton Garden Inn Austin Downtown Convention Center
(512) 480-8181
Booking link: https://www.hilton.com/en/book/reservation/rooms/?ctyhocn=AUSGIGI&arrivalDate=2022-06-08&departureDate=2022-06-12&room1NumAdults=1&cid=OM%2CWW%2CHILTONLINK%2CEN%2CDirectLink  

Refund Policy

All ticket purchases are non-refundable.  In the event that ASKP3 is unable to hold the event in person, all tickets will be honored for the virtual event.  In the event we are unable to hold the conference due to circumstances beyond our control, all purchases will be refunded in full. 


Registration Insurance

ASKP3 is pleased to offer the opportunity for attendees to independently purchase registration insurance through the Registration Saver Program offered by Next Wave.  ASKP3 encourages all attendees to consider this option.  Please be sure to check the policy for details. 


Conference T-shirts

There is an opportunity to purchase a conference t-shirt online when you purchase your ticket.  We will not be offering t-shirts at the conference for sale.  The purchase price is $17.


We look forward to seeing you and networking with you at the conference!


Sincerely,


The Board of Directors

American Society of Ketamine Physicians,

Psychotherapists & Practitioners

 

 

 

American Society of Ketamine Physicians, Psychotherapists & Practition

www.askp.org

The American Society of Ketamine Physicians, Psychotherapists, & Practitioners is a non-profit group of professionals dedicated to the safe clinical use of ketamine for mental health disorders and pain conditions.

Contact the Organizer

Abid Nazeer, MD, FASAM
Chief Medical Officer
Wesana Health / APS Ketamine

Dr. Abid K. Nazeer M.D., FASAM is a practicing psychiatrist with board certifications in both psychiatry and addiction medicine and is the current Chief Medical Officer for Wesana Health and Vice President of the American Association of Psychedelics. He is a medical advisor for several companies including Healing Maps and Speranza Therapeutics and has held multiple other medical director or leadership positions in healthcare. After initially serving as Chief Resident at Louisiana State University, Dr. Nazeer went on to lead the PTSD clinic at Overton Brooks VA Medical Center before entering private practice settings. Until recently, he held the role of Chief Medical Officer for Symetria Recovery, a comprehensive opioid treatment program, and was able to help develop the care model and support growth to 12 clinics nationally. In 2016, he founded Advanced Psychiatric Solutions (APS Ketamine), pioneering the first dedicated outpatient psychiatric based ketamine clinic in the Midwest. APS Ketamine, now Wesana Clinics, has grown to a 3rd Chicago area location opening soon, and has successfully completed over 4000 IV ketamine treatments for mental health and substance use disorders. Dr. Nazeer designed his clinic model to incorporate comprehensive psychiatric services such as traditional pharmacotherapy, psychotherapy, neurocognitive testing, neuromodulation, pharmacogenetics, and outcome measurement, as the foundation of ketamine therapy. He is regarded as an expert in the clinical application of ketamine within the psychiatric setting and provides peer education about ketamine topics such as screening, assessment, quality assurance, and standards of care.

About Abid Nazeer, MD, FASAM

Chief Medical Officer
Wesana Health / APS Ketamine
Andrea Turnipseed, LCSW-S
co-founder and Executive Director
Roots Behavioral Health

Andrea Turnipseed is the co-founder and Executive Director of Roots Behavioral Health, a local psychiatric practice offering innovative and holistic mental healthcare. Andrea has training and a background in adult mental health and has worked with clients in acute inpatient and outpatient psychiatric settings, facilitating both group and individual therapy. Under her leadership, since 2016, the practice has grown to 2 locations employing over 40 individuals who treat over 10,000 Central Texans. Focusing on the combined goals and strengths of an individual Andrea creates space for clients and employees to reach their highest potential. As the first practitioners in Texas to provide Ketamine Assisted Psychotherapy, Andrea, has co-authored cardinal research, supervises therapists, and speaks to the various organizations seeking knowledge of Ketamine and clinic development.

About Andrea Turnipseed, LCSW-S

co-founder and Executive Director
Roots Behavioral Health
Brandon Kitay, MD, PhD
Director of Behavioral Health Integration
Emory Healthcare

Dr. Kitay is an Assistant Professor of Psychiatry and Behavioral Sciences at the Emory School of Medicine, Director of Behavioral Health Integration for the Emory Healthcare Network, and an "Interventional Psychiatrist” with deep expertise in neuromodulation and advanced pharmacotherapies for severe and treatment refractory psychiatric disorders. Through the development of scalable, stepped-care initiatives, his work aims to improve timely access to evidence-based treatment through the natural course of psychiatric disorders managed within large health systems. This includes mitigating barriers and time to referral for therapies like ketamine/esketamine, as well as optimizing care through a course of treatment.

About Brandon Kitay, MD, PhD

Director of Behavioral Health Integration
Emory Healthcare
Brent Turnipseed, MD
Medical Director and Principal Investigator
Roots Behavioral Health

Brent is a native Austinite and board-certified psychiatrist. He co-founded Roots Behavioral Health with his wife, Andrea, in 2016 with the goal of making innovative psychiatric care more accessible to Central Texans. Brent and Andrea began offering ketamine-assisted psychotherapy (KAP) to their patients in 2018 and Roots has now administered over 4,000 ketamine sessions. Brent--in conjunction with Phil Wolfson and the Ketamine Training Center--published the first observational study of KAP. Under Brent's clinical leadership, Roots is now recognized as one of the preeminent models of holistic behavioral healthcare, and he hopes to transform the industry, beginning with Texas.

About Brent Turnipseed, MD

Medical Director and Principal Investigator
Roots Behavioral Health
Brittany O'Brien, PhD
Psychologist
Baylor College of Medicine

Dr. O’Brien is a clinical psychologist and assistant professor at Baylor College of Medicine. She received her doctoral degree from the New School for Social Research in New York City and completed her post-doctoral fellowship at Baylor College of Medicine. She is a coinvestigator on several federal, foundation, and industry sponsored trials investigating novel treatments for patients with treatment-resistant mood, anxiety, and trauma related disorders. Her research focuses on factors that may enhance or challenge treatment response, such as the influence of early life stress on treatment resistant depressed patients receiving ketamine therapy. Her clinical work has spanned a variety of settings, age groups and psychiatric disorders. She currently sees patients for psychotherapy and oversees training for pre and post doctoral trainees in the Baylor Psychiatry Mood Disorders Clinic and has a particular interest in working with patients who experience chronic and treatment resistant symptoms using evidence-based and patient-centered approaches.

About Brittany O'Brien, PhD

Psychologist
Baylor College of Medicine
Daniel Sternthal, JD
Shareholder
Munsch Hardt

Daniel is Board Certified in Health Law by the Texas Board of Legal Specialization and is a recognized authority on regulatory, business, and policy issues related to health care. For the last 20 years Daniel has focused his practice on the health care industry, on issues relating to regulatory, operational and transactional matters. Daniel earned his JD from The University of Texas School of Law. He holds a master's degree from The Hebrew University of Jerusalem and a bachelor's degree from McGill University.

About Daniel Sternthal, JD

Shareholder
Munsch Hardt
Dominic Sisti, PhD
Associate Professor in the Department of Medical Ethics & Health Policy
Perelman School of Medicine at the University of Pennsylvania

Dominic Sisti, PhD, is an assistant professor in the Department of Medical Ethics & Health Policy at the University of Pennsylvania. He holds secondary appointments in the Department of Psychiatry, where he directs the ethics curriculum in the residency program, and the Department of Philosophy. Dr. Sisti examines ethical and policy challenges in mental health care, including long-term psychiatric care for individuals with serious mental illness and ethical issues in psychedelic research and clinical application. Dr. Sisti's writings have appeared in medical and bioethics journals such as JAMA, JAMA Psychiatry, Psychiatric Services, the Hastings Center Report, and the Journal of Medical Ethics. His scholarship has also been featured in popular media outlets such as the New York Times, The Economist, NPR, the Philadelphia Inquirer, Slate, and The Atlantic. He is co-editor of three books including Applied Ethics in Mental Healthcare: An Interdisciplinary Reader. Dominic Sisti received his bachelor's degree in biology from Villanova University, a master of bioethics from the University of Pennsylvania, and his doctorate in philosophy from Michigan State University. Sisti was an Edmund Pellegrino Fellow at the Center for Clinical Bioethics at Georgetown University.

About Dominic Sisti, PhD

Associate Professor in the Department of Medical Ethics & Health Policy
Perelman School of Medicine at the University of Pennsylvania
Erin Amato, MD
Medical Director
Montana Psychiatry & Brain Health Center

Erin Amato, MD is an award-winning speaker, interventional psychiatrist in Billings, Montana who has specialized in cutting edge treatments for treatment-refractory psychiatric disorders since 2014. She was the first physician in her region to offer TMS, ketamine, and esketamine and specializes in integrative approaches to treating complex psychiatric disorders. She is double board certified in general psychiatry and child and adolescent psychiatry and has also completed fellowship programs in Integrative Psychiatry through IPI and Metabolic, Functional, and Anti-Aging Medicine through the American Academy of Anti-Aging Medicine. She has appeared as a mental health media expert on multiple TV news outlets and is passionate about advocacy and education about cutting-edge depression treatments.

About Erin Amato, MD

Medical Director
Montana Psychiatry & Brain Health Center
Gita Vaid, MD
Psychiatrist

Gita Vaid, MD is a board certified psychiatrist and psychoanalyst practicing ketamine assisted psychotherapy in New York City. She is a co-founder of the Center for Natural Intelligence(www.thecenterfornaturalintelligence.com), a multidisciplinary laboratory dedicated to psychedelic psychotherapy innovation and clinical practice. Dr Vaid completed her psychiatric residency training at NYU Medical Center, psychoanalytic training at the Psychoanalytic Association of New York. She trained as a fellow in clinical psychopharmacology and neurophysiology at New York Medical College and completed a research fellowship at NYU Medical Center. Dr Vaid serves as the Director of Psychedelic Awareness at The Chopra Foundation and is on Faculty at The Ketamine Training Center.

About Gita Vaid, MD

Psychiatrist
Hamilton Morris
journalist, researcher and creator of the television series Hamilton's Pharmacopeia

Hamilton Morris is a medicinal chemist at the USciences Philadelphia Psychedelic Discovery Center as well as the creator and director of the documentary series Hamilton's Pharmacopeia.

About Hamilton Morris

journalist, researcher and creator of the television series Hamilton's Pharmacopeia
Jason Wallach, PhD
Assistant Professor of Pharmaceutical Sciences
USciences

Dr. Jason Wallach obtained his PhD in Pharmacology and Toxicology from the University of the Sciences, where he is also currently an assistant professor in the Department of Pharmaceutical Sciences. Dr. Wallach also has an appointment to the Substance Use Disorders Institute at University of the Sciences. He advises several pharmaceutical companies in drug development, leading several drug discovery projects. Dr. Wallach has over a decade of research experience investigating N-methyl-D-aspartate receptor (NMDAR) antagonists and 5-HT2A receptor agonists. His research interests include the chemistry and pharmacology of dissociative and psychedelic drugs, where he has authored many peer-reviewed publications and book chapters.

About Jason Wallach, PhD

Assistant Professor of Pharmaceutical Sciences
USciences
Jeffrey Becker, MD
Physician
Jeffrey Becker, MD, Inc.

Jeffery Becker has over 20 years of experience with ketamine and functional techniques mental health care. He trained many early adopters in the field and teaches widely regarding the use of symbolism and the classic trope of Encounter with Self in supporting and interpreting the psychic states produced by ketamine in psycholtherapy. He is also known for translational theories integrating the neuroscience of ketamine's pharmacodynamic effects with long-standing psycho-spiritual disciplines, such as transpersonal psychology and mysticism. He maintains a private practice in Santa Barbara and is Chief Scientific Officer of Bexson Biomedical, which is dedicated to dynamic delivery of ketamine, psychedelics and other small molecules via wearable subcutaneous patch pump technology.

About Jeffrey Becker, MD

Physician
Jeffrey Becker, MD, Inc.
John Dougherty III, DO
Psychiatrist
Initia Nova Delaware

"Dr. Dougherty completed his psychiatric residency at The Johns Hopkins Hospital with special training in Traumatic brain injury. Dr. Dougherty is currently a part-time associate professor of psychiatry and behavioral sciences at Johns Hopkins University. He is the associate medical director at Harbor of Grace Recovery, a dual diagnosis treatment center specializing in the treatment of first responders, fire fighters, police officers and military. In addition, he currently works in a private practice in the suburbs of Philadelphia where he specializes in the treatment of those with Traumatic brain injuries as well as athletes with mental health disorders. He is a member of the International Society of Sports Psychiatrist (ISSP) and a collaborator for the Becoming Counseling and Wellness which is the official national counseling provider for the Hall of fame health (HOFH) for retired NFL players and their families. He has performed over 2000 ketamine infusions to date and is the medical director of Initia Nova Delaware ketamine treatment center."

About John Dougherty III, DO

Psychiatrist
Initia Nova Delaware
L. Alison McInnes, MD, MS
VP of Medical Affairs
Osmind

Dr. Alison McInnes is Vice President, Medical Affairs at Osmind. She is a nationally recognized expert in psychiatry and mood and anxiety disorders, having specialized in treating refractory disease for over a decade. She is additionally an expert in ketamine treatment and psychedelic medicine. She founded and served as Medical Director for Kaiser Permanente's ketamine infusion therapy program for a number of years. She was previously an Associate Professor of Psychiatry at Mount Sinai School of Medicine for 8 years where she ran a lab in psychiatric genetics, and was also an adjunct clinical professor at UCSF. Dr. McInnes is regularly invited to speak at national and international conferences and is asked to consult for biopharmaceutical companies working at the cutting edge of neuropsychiatry. In her current clinical practice, she focuses on treatment-resistant mood disorders and complex cases.

About L. Alison McInnes, MD, MS

VP of Medical Affairs
Osmind
Lisa Harding, MD
Medical Director
Depression MD

Lisa Harding MD, Board Certified Psychiatrist and depression expert is specially trained in providing all treatment types for depression. She has completed over 4,000 procedures in Electroconvulsive therapy (ECT), IV Ketamine, Spravato and Transcranial Magnetic Stimulation (TMS). She is also experienced in managing complex medication regimen and skilled in various psychotherapy methods. She is the medical director of Depression MD a TRD Clinic in CT and she is a clinical Instructor in the department of psychiatry at the Yale School of Medicine

About Lisa Harding, MD

Medical Director
Depression MD
Michael Bloch, MD, MS
Psychiatrist
Yale University

Michael H. Bloch, M.D., M.S. graduated from Yale School of Medicine and completed his child and adult psychiatry training at Yale. His research interests focus on studying Tourette syndrome (TS), obsessive-compulsive disorder (OCD) and trichotillomania (TTM) across the lifespan and developing better pharmacological treatments for children with depression, anxiety and ADHD. His research focuses on developing better treatments for children and adults with these conditions particularly through clinical trials and meta-analysis. In recent years he has focused on developing better treatments for adolescents with depression and suicidality.

About Michael Bloch, MD, MS

Psychiatrist
Yale University
Natalie Gukasyan, MD
Medical Director
Johns Hopkins Center for Psychedelic and Consciousness Research

Natalie Gukasyan, M.D. is a psychiatrist and Assistant Professor at Johns Hopkins University. After receiving her M.D. from Tulane University School of Medicine Dr. Gukasyan completed her internship and residency in psychiatry at Johns Hopkins. She went on to complete a NIDA T32 funded fellowship in behavioral pharmacology under the mentorship of Dr. Roland Griffiths, focusing on safety and efficacy of psilocybin-assisted therapy for people with mood and eating disorders. Dr. Gukasyan now serves as the Medical Director of the Johns Hopkins Center for Psychedelic and Consciousness Research, where she has continued research on novel treatment approaches involving psychedelics. Dr. Gukasyan is also a clinician at the Johns Hopkins Bayview Community Psychiatry Program serving patients with co-occurring mental illness and addictive disorders.

About Natalie Gukasyan, MD

Medical Director
Johns Hopkins Center for Psychedelic and Consciousness Research
Nicholas Bruss, EdD, LMFT
Speaker and Psychotherapist

Dr. Nicholas Bruss is an integrative psychotherapist and clinical researcher who specializes in helping people heal and grow with psychedelics-assisted psychotherapies. He is a co-therapist and associate supervisor on the MAPS-sponsored FDA Phase III clinical trial of MDMA-assisted therapy for PTSD in Los Angeles, CA. Nicholas has been a certified Internal Family Systems (IFS) therapist since 2015 and has been providing ketamine-assisted psychotherapy (KAP) since 2017. He is a leader in psychedelic-assisted IFS therapy, a volunteer with MAPS's Zendo Project, and a co-founder at the Psychedelic Coalition for Health (PCH) where he trains clinicians in psychedelic-assisted therapy.

About Nicholas Bruss, EdD, LMFT

Speaker and Psychotherapist
Nykol Bailey, CRNA, PMHNP
Owner/Operator
Boise Ketamine Clinic

Nykol Bailey Rice is a Certified Registered Nurse Anesthetist as well as a Psychiatric Mental Health Nurse Practitioner who has been working with ketamine at her practice, Boise Ketamine Clinic, since 2016. She is a current ASKP3 board member where she chairs both the Advance Practice Provider Panel and the Writer's Panel. She is also an adjunct lecturer at Boise State University and Middle Tennessee School of Anesthesia. She is passionate about suicide prevention and the future of psychedelic medicine.

About Nykol Bailey, CRNA, PMHNP

Owner/Operator
Boise Ketamine Clinic
Patrick Oliver, MD
Medical Director
MindPeace Clinics

Dr. Patrick A. Oliver, MD is a Board Certified Emergency Physician who founded MindPeace Clinics in 2017. Dr. Oliver is very passionate about prevention of suicide, and focused his energy in both caring for patients and working with the team at the Medical College of Virginia to publish his data from the first 500+ patients in his practice. Dr. Oliver has been joined with eight other physicians, and expanded to three clinics in the Commonwealth of Virginia and a fourth in San Francisco with additional expansion plans. Additionally, Dr. Oliver and his team have developed a niche Electronic Medical Record system specifically for Ketamine Therapeutics that has been used to collect the data for this paper. Dr. Oliver and his team are already working on publishing an additional paper next year with the data from more than 1,000 patients, 10,000 infusions and more than 20,000 surveys.

About Patrick Oliver, MD

Medical Director
MindPeace Clinics
Patrick Sullivan, DO
Medical Director
Initia Nova Medical Solutions, LLC

Dr. Patrick Sullivan is board certified in emergency medicine and has worked most of his career in a psychiatric emergency department. He currently works in a neurologic ED where his primary focus is in treating stroke, seizure and headache. He is also the founder and medical director of Initia Nova where he specializes in treating depression, PTSD, alcohol addiction and headache. Primary treatment modalities are ketamine infusions, ketamine assisted psychotherapy, nerve blocks and transcranial magnetic stimulation.

About Patrick Sullivan, DO

Medical Director
Initia Nova Medical Solutions, LLC
Philip Wolfson, MD
Director
Center for Transformational Psychotherapy

Phil Wolfson MD is the creator of a new psychotherapy modality based on use of the medicine ketamine—Ketamine Assisted Psychotherapy (KAP). Phil is the CEO of the non-profit Ketamine Research Foundation and directs the training of KAP practitioners through The Ketamine Training Center's now numbering over 450 practitioners across the US and Internationally. KRF's Ketamine Psychotherapy Associates membership organization promotes the development of KAP practices and KAP wisdom on an ongoing basis. He is the author of The Ketamine Papers and Noe A Father/Son Song of Love, Life, Illness and Death. He has been the Principal Investigator of the MAPS.org Phase 2 study of MDMA treatment for individuals with life-threatening illnesses. Dr. Wolfson's work is the result of an intense, now many decades long clinical psychiatry/psychotherapy practice. He is a Founder of Progressive Therapeutics Inc, an exciting new commercial psychedelic and psychoactive drug development corporation that is allied with his non-profit. The second volume of The Ketamine Papers is being prepared for publication in 2022. He was just featured in a lead article in the New Yorker on 12/29/21. KRF's research.

About Philip Wolfson, MD

Director
Center for Transformational Psychotherapy
Randall Malchow, MD
Medical Director
AMG Ketamine and Wellness

Dr Malchow is passionate about reducing chronic pain and suffering from long-term opioids, in order for patients to live an abundant life. He served 25 years of military service holding various positions including Anesthesiology Residency Program Director and Chief of Anesthesiology at Brooke Army Medical Center in San Antonio, TX. In 2008, he accepted a clinical appointment at Vanderbilt University Medical Center in Nashville, where he created the Regional Anesthesia and Acute Pain Fellowship, significantly expanding the use of advanced techniques for multimodal anesthesia and pain control. He established one of the few ketamine infusion centers in the Veteran Health Administration, specifically targeting opioid cessation/reduction. He spoke at the 2018 Annual ASKP meeting highlighting his experience with ketamine in the veteran population. He has been awarded the Army’s Legion of Merit, the Outstanding Program Director Award in 2006, and the Golden Apple Teaching Award in 2010. He has presented hundreds of lectures on a wide range of anesthesia and analgesia topics including the use of ketamine to regional, national, and international audiences, has published over 20 peer-reviewed manuscripts, and has a heart for the poor and the oppressed serving regularly on international humanitarian medical missions for the past 20 years.

About Randall Malchow, MD

Medical Director
AMG Ketamine and Wellness
Rena Beyer, MSW, LCSW
Psychotherapist
Fostering Greatness

Rena Beyer is a mental health therapist from New Jersey and the owner of Fostering Greatness, her mental health private practice which she opened in 2016 serving clients in both New Jersey and Delaware. Rena’s practice focuses on clients who are adolescents through adults struggling with trauma, depression, anxiety, and/or fertility concerns. Rena began working with Ketamine as a KAP therapist in 2017 alongside Dr. Patrick Sullivan at his practice, Initia Nova, where she offers preparation sessions, IV KAP sessions, and integration sessions. Rena is a member of the Board of Directors for ASKP3 and is the board liaison for the Therapist Advisory Panel of ASKP3. Rena also works as a life coach for mothers of toddlers.

About Rena Beyer, MSW, LCSW

Psychotherapist
Fostering Greatness
Rupert McShane, MD, FRCPsych
Associate Professor
University of Oxford

Dr McShane runs a ketamine clinic in Oxford and is coorganiser of a ketamine-focussed conference which is held in Oxford regularly and of the Ketamine International Journal Club which runs every other week. He is a psychiatrist and also runs an ECT clinic and a memory clinic.

About Rupert McShane, MD, FRCPsych

Associate Professor
University of Oxford
Samuel Wilkinson, MD
Physician
Yale University

Dr. Wilkinson graduated from Johns Hopkins School of Medicine in 2012 and later completed his psychiatry residency and fellowship training at Yale University. He is currently an Assistant Professor at Yale and the Associate Director of the Yale Depression Research Program. His work could be described broadly as improving therapies and implementation of treatments in interventional psychiatry.

About Samuel Wilkinson, MD

Physician
Yale University
Sandhya Prashad, MD
Physician
Houston Ketamine Therapeutics

Sandhya Prashad, MD is a board-certified psychiatrist in private practice specializing in interventional modalities for treatment resistant disorders with a particular interest and expertise in ketamine therapy. She completed both medical school and psychiatry residency at Baylor College of Medicine. She is a founder and the current president of the American Society of Ketamine Physicians, Psychotherapists and Practitioners. Dr. Prashad has also been appointed as a clinical assistant professor at Baylor College of Medicine in the Menninger Department of Psychiatry and Behavioral Sciences.

About Sandhya Prashad, MD

Physician
Houston Ketamine Therapeutics
Sanjay Mathew, MD
Physician
Baylor College of Medicine

Sanjay J. Mathew, M.D. is the Marjorie Bintliff Johnson and Raleigh White Johnson, Jr. Vice Chair for Research and Professor in the Menninger Department of Psychiatry & Behavioral Sciences at Baylor College of Medicine. He graduated from Dartmouth College and Baylor College of Medicine, and trained in psychiatry and research at Columbia University and the New York State Psychiatric Institute. Prior to his current Baylor position, he served as faculty at the Icahn School of Medicine at Mount Sinai, where he co-directed the Mood and Anxiety Disorders Program. His research program focuses on experimental therapeutics and pathophysiology related to treatment-resistant mood and anxiety disorders and PTSD, with a particular focus on rapid-acting glutamate-modulating agents such as ketamine. Dr. Mathew has authored or co-authored over 150 manuscripts and book chapters, and serves on the editorial board of several journals. In 2016, he co-edited the book “Ketamine for Treatment-Resistant Depression.” He serves on the Boards of the American Society of Clinical Psychopharmacology and the Anxiety and Depression Association of America, and is an elected fellow of the American College of Neuropsychopharmacology.

About Sanjay Mathew, MD

Physician
Baylor College of Medicine
Steve Levine, MD
SVP of Patient Access and Medical Affairs
Compass Pathways

Dr. Steve Levine is a board-certified psychiatrist internationally recognized for his contributions to advancements in mental health care. He currently serves as Senior Vice President of Patient Access and Medical Affairs for COMPASS Pathways and is co-founder and Chairman of the Board of Heading Health. Dr. Levine completed internship and residency in psychiatry at New York – Presbyterian Hospital – Weill Cornell. He then completed fellowship subspecialty training in psychosomatic medicine/psycho-oncology at Memorial Sloan Kettering Cancer Center/New York Presbyterian Hospital. He has published extensively in both peer-reviewed journals and popular media, presented to both professional and lay audiences around the world, served in leadership roles for professional societies and not-for-profit entities, and received numerous awards for leadership and service.

About Steve Levine, MD

SVP of Patient Access and Medical Affairs
Compass Pathways
Steven Mandel, MD
Medical Director
Ketamine Clinics Los Angeles

Dr. Steven L. Mandel, Founder & President of Ketamine Clinics Los Angeles, is an internationally recognized expert and pioneer in the use of Ketamine Infusion Therapy to treat mental health disorders and chronic pain. Dr. Mandel has more than 40 years of experience utilizing ketamine as a board-certified anesthesiologist. He also earned his master’s degree in psychology. Dr. Mandel is also a founder of the American Society of Ketamine Physicians, Psychotherapists and Practitioners (ASKP3), was the organization’s first president, and is currently an active board member. Dr. Mandel lives in Los Angeles with his wife, with whom he has four grown children, and their golden retriever Magellan. When he isn’t caring for patients, Dr. Mandel enjoys sailing and skiing.

About Steven Mandel, MD

Medical Director
Ketamine Clinics Los Angeles
Stuart Miller, JD
Shareholder
Munsch Hardt

Stuart represents health care clients in a variety of corporate and regulatory matters such as their operational, governance, formation and restructuring issues, joint ventures, mergers and acquisitions, employment matters, compliance and reimbursement controversies. He also regularly advises health care clients regarding compliance with the federal Anti-Kickback Act, the Stark Act and the Health Insurance Portability and Accountability Act (HIPAA), the corresponding state laws and issues relevant legal opinions relating to such matters. Stuart has been recognized as a leading attorney in his field by Chambers USA Texas, The Best Lawyers in America and Texas Super Lawyers. He has previously served as president of the Greater Houston Healthcare Alliance, chair of the Houston Bar Association's Health Law Section, and as an adjunct professor at the University of Houston Clear Lake where he taught a graduate level course on the legal aspects of health care administration.

About Stuart Miller, JD

Shareholder
Munsch Hardt
Tatiana Santini, MA
Clinical Development Lead, Psychotherapy
Beckley PsyTech Ltd.

Tatiana is a Registered Psychotherapist, Ketamine Assisted Psychotherapist, working primarily with trauma and substance use disorders. Tatiana completed CIIS Psychedelic Therapies, Phil Wolfson's KTC training and MAPS MDMA training, and is currently completing 3-year Psychedelic Therapy Training with AWE Foundation.

About Tatiana Santini, MA

Clinical Development Lead, Psychotherapy
Beckley PsyTech Ltd.

About Beyond Marketing

www.beyondmarketing.net Sponsor Logo

About Ketamine Media

https://ketaminemedia.com/ Sponsor Logo

About BrainsWay

https://www.brainsway.com/ Sponsor Logo

About Caretaker Medical

www.caretakermedical.net Sponsor Logo

About Clinical TMS Society

www.clinicaltmssociety.org Sponsor Logo

About Eating Recovery Center and Pathlight Mood & Anxiety Center

https://www.pathlightbh.com/ Sponsor Logo

About Homecoming

www.homecoming.health/ Sponsor Logo

About Integrative Psychiatry Institute

psychiatryinstitute.com Sponsor Logo

About MagVenture

www.magventure.com Sponsor Logo

About MNH TMS & Psychiatry Services

www.TMSstartitup.com Sponsor Logo

About Munsch Hardt

https://www.munsch.com/ Sponsor Logo

About Osmind

www.osmind.org Sponsor Logo

About OutcomeMD

https://outcomemd.com/ Sponsor Logo

About Turnwell Mental Health Network

http://turnwellmentalhealth.com/ Sponsor Logo

About Bexson Biomedical, Inc.

www.bexsonbiomedical.com Sponsor Logo

12:00 PM

Registration

12:00 PM - 07:00 PMCongressional Foyer
01:00 PM

Introductory Pre-Lectures (Additional Ticket Purchase Required)

01:00 PM - 05:15 PMSage
  • +3
  • Erin Amato, MD

    Medical Director

06:00 PM

Welcome Cocktail Reception

06:00 PM - 07:30 PMCongressional Foyer

Sponsors

07:00 AM

Breakfast and Special Thought Leader Presentation

07:00 AM - 08:00 AMCongressional A

Sponsors

07:00 AM

Registration

07:00 AM - 05:30 PMCongressional Foyer
08:15 AM
Main Stage

Opening Remarks

08:15 AM - 08:30 AMCongressional B
  • Sandhya Prashad, MD

    Physician

08:30 AM
Main Stage

Maintaining Ethical and Professional Boundaries with Patients: Issues to Consider

08:30 AM - 09:20 AMCongressional B
  • Dominic Sisti, PhD

    Associate Professor in the Department of Medical Ethics & Health Policy

09:20 AM
Main Stage

Legal Considerations in Ketamine Clinics

09:20 AM - 10:00 AMCongressional B
  • +1
  • Daniel Sternthal, JD

    Shareholder

10:00 AM

Break

10:00 AM - 10:10 AMCongressional Foyer
10:10 AM
Main Stage

Psychedelic Pharmacology

10:10 AM - 10:50 AMCongressional B
  • +1
  • Hamilton Morris

    journalist, researcher and creator of the television series Hamilton's Pharmacopeia

10:50 AM
Main Stage

Esketamine and Cognitive Behavioral Therapy

10:50 AM - 11:30 AMCongressional B
  • Samuel Wilkinson, MD

    Physician

11:30 AM

Lunch

11:30 AM - 12:30 PMCongressional A
12:30 PM
Main Stage

Ketamine and Esketamine: Lessons to Inform Emerging Psychedelic Delivery Models

12:30 PM - 01:10 PMCongressional B
  • Steve Levine, MD

    SVP of Patient Access and Medical Affairs

01:10 PM
Main Stage

Psilocybin-Assisted Therapy for Major Depressive Disorder: Current Evidence and Future Directions

01:10 PM - 01:50 PMCongressional B
  • Natalie Gukasyan, MD

    Medical Director

01:50 PM
Main Stage

Ketamine Therapy: Debate & Implications

01:50 PM - 02:30 PMCongressional B
  • +2
  • Lisa Harding, MD

    Medical Director

02:30 PM
Main Stage

Expanding Scope of Consciousness: Understanding the Neurobiology and Symbolism of Ketamine and Psychedelic States

02:30 PM - 03:10 PMCongressional B
  • Jeffrey Becker, MD

    Physician

03:10 PM

Break

03:10 PM - 03:45 PMCongressional Foyer
03:45 PM
Breakout

Management of Patients Who Stop Responding and Non-Responders

03:45 PM - 04:30 PMSage
  • +1
  • Lisa Harding, MD

    Medical Director

Ketamine Services and the Managed Care Model

03:45 PM - 04:30 PMCongressional B
  • +1
  • Andrea Turnipseed, LCSW-S

    co-founder and Executive Director

Ketamine & Pain

03:45 PM - 04:30 PMPoppy
  • +1
  • Nykol Bailey, CRNA, PMHNP

    Owner/Operator

Incorporating Functional and Integrative Mental Health Treatments into Ketamine-Related Care

03:45 PM - 04:30 PMPrimrose
  • +1
  • Erin Amato, MD

    Medical Director

Opening Space for Parts: Ketamine-Assisted Internal Family Systems Therapy

03:45 PM - 04:30 PMCongressional A
  • Nicholas Bruss, EdD, LMFT

    Speaker and Psychotherapist

04:45 PM
Breakout

Management of Patients Who Stop Responding and Non-Responders

04:45 PM - 05:30 PMSage
  • +1
  • Lisa Harding, MD

    Medical Director

Ketamine Services and the Managed Care Model

04:45 PM - 05:30 PMCongressional B
  • +1
  • Andrea Turnipseed, LCSW-S

    co-founder and Executive Director

Ketamine & Pain

04:45 PM - 05:30 PMPoppy
  • +1
  • Nykol Bailey, CRNA, PMHNP

    Owner/Operator

Incorporating Functional and Integrative Mental Health Treatments into Ketamine-Related Care

04:45 PM - 05:30 PMPrimrose
  • +1
  • Erin Amato, MD

    Medical Director

Ketamine Assisted Psychotherapy- Challenging Cases

04:45 PM - 05:30 PMCongressional A
  • +1
  • Philip Wolfson, MD

    Director

07:00 AM

Registration

07:00 AM - 04:15 AMCongressional Foyer
07:00 AM

Breakfast

07:00 AM - 08:00 AMCongressional A
08:00 AM
Main Stage

Ketamine and Opioid Dependence: A New Frontier?

08:00 AM - 08:40 AMCongressional B
  • Randall Malchow, MD

    Medical Director

08:40 AM
Main Stage

Ketamine for Migraine and Headache Disorders

08:40 AM - 09:20 AMCongressional B
  • +1
  • Nykol Bailey, CRNA, PMHNP

    Owner/Operator

09:20 AM
Main Stage

Ketamine Assisted Psychotherapy--the Primacy of the Subjective

09:20 AM - 10:00 AMCongressional B
  • Philip Wolfson, MD

    Director

10:00 AM

Break

10:00 AM - 10:10 AMCongressional Foyer
10:10 AM
Main Stage

Esketamine: A Conversation About Access to Care

10:10 AM - 10:50 AMCongressional B
  • Lisa Harding, MD

    Medical Director

10:50 AM
Main Stage

Challenges and Opportunities for Collaborative Care in the Delivery of Ketamine/Esketamine Therapy

10:50 AM - 11:30 AMCongressional B
  • Brandon Kitay, MD, PhD

    Director of Behavioral Health Integration

11:30 AM

Lunch

11:30 AM - 12:30 PMCongressional A
12:30 PM
Main Stage

Ketamine and Late-Life Depression: Perspectives on Recent Research

12:30 PM - 01:10 PMCongressional B
  • Sanjay Mathew, MD

    Physician

01:10 PM
Main Stage

Emerging Depression Treatment: Ketamine for Treatment-Resistant Depression in Adolescents

01:10 PM - 01:50 PMCongressional B
  • Michael Bloch, MD, MS

    Psychiatrist

01:50 PM
Main Stage

Outcomes of Ketamine Intravenous Therapy (KIT) for Depression and Anxiety in the Real-World Part II

01:50 PM - 02:30 PMCongressional B
  • L. Alison McInnes, MD, MS

    VP of Medical Affairs

02:30 PM
Main Stage

Clinical Effectiveness of Intravenous Racemic Ketamine Infusions in a Large Community Sample with Suicidal Ideation, TRD, and Generalized Anxiety Disorder

02:30 PM - 03:10 PMCongressional B
  • Patrick Oliver, MD

    Medical Director

03:10 PM

Break

03:10 PM - 03:25 PMCongressional Foyer
03:25 PM
Breakout

TMS & Ketamine Used in Combination

03:25 PM - 04:10 PMPrimrose
  • +1
  • Patrick Sullivan, DO

    Medical Director

Billing and Insurance

03:25 PM - 04:10 PMCongressional B
  • Lisa Harding, MD

    Medical Director

Difficult Cases/ Personality Disorders/ Boundaries

03:25 PM - 04:10 PMSage
  • +1
  • Erin Amato, MD

    Medical Director

Mastering Hybrid Intramuscular Dosing in Ketamine Assisted Psychotherapy

03:25 PM - 04:10 PMPoppy
  • +1
  • Gita Vaid, MD

    Psychiatrist

Where Does Ketamine Fit in the Future Psychedelic Landscape?

03:25 PM - 04:10 PMCongressional A
  • Abid Nazeer, MD, FASAM

    Chief Medical Officer

04:15 PM
Breakout

Ketamine Assisted Psychotherapy - Research, Frameworks and Application

04:15 PM - 05:00 PMPrimrose
  • +1
  • Brittany O'Brien, PhD

    Psychologist

Difficult Cases/ Personality Disorders/ Boundaries

04:15 PM - 05:00 PMSage
  • +1
  • Erin Amato, MD

    Medical Director

Esketamine in Private Practice: Cases from the Experts

04:15 PM - 05:00 PMPoppy
  • +1
  • Lisa Harding, MD

    Medical Director

Ketamine Assisted Psychotherapy- Challenging Cases

04:15 PM - 05:00 PMCongressional B
  • +1
  • Philip Wolfson, MD

    Director

Where Does Ketamine Fit in the Future Psychedelic Landscape?

04:15 PM - 05:00 PMCongressional A
  • Abid Nazeer, MD, FASAM

    Chief Medical Officer

  • Integer nulla lorem, pellentesque eget eros malesuada, semper bibendum felis. Proin quis est egestas, ultrices purus tempor, aliquet erat. Nullam molestie, neque at hendrerit semper, dui lacus eleifend arcu, quis mattis augue leo condimentum dui. Nunc vehicula eleifend risus vitae luctus. Sed sed sem nibh. Nam sit amet massa ullamcorper, iaculis felis id, ullamcorper libero. Aenean aliquet orci quis nisi interdum faucibus. Maecenas sollicitudin, nunc vitae tempus feugiat, arcu elit egestas diam, sit amet maximus neque turpis ac quam. Curabitur at ligula eget turpis pellentesque vestibulum eu id ante. Cras eget turpis mauris. Vestibulum vitae quam elit. Suspendisse bibendum at ipsum nec tempor. Ut in tristique nibh. Aliquam erat volutpat. In hac habitasse platea dictumst.

    Vivamus tempor viverra enim, commodo faucibus quam porta sed. Sed et varius nunc. Fusce cursus sem nec tellus accumsan, sed laoreet nisi vulputate. Praesent varius quis turpis in aliquam. Phasellus nisl velit, porttitor eget risus sed, interdum elementum nibh. Praesent eget ante bibendum quam suscipit accumsan sit amet eu nisi. Ut eget facilisis risus. Proin molestie lorem ut interdum finibus. Sed pretium ut sapien at dictum. Sed sit amet dolor tincidunt turpis tincidunt ultricies et et neque.

    Nam non augue a lorem tempor sodales. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia Curae; Quisque ullamcorper lobortis rhoncus. Morbi nec dui vitae odio ultricies posuere ac nec turpis. Vestibulum efficitur lectus sem, sed volutpat quam congue at. Nulla quis aliquam ex. Vestibulum eget felis consectetur, efficitur risus non, dapibus tellus. Aliquam ac gravida dui. Donec vel est a arcu tristique egestas id vitae neque. Nullam varius odio eget leo porttitor, pharetra rhoncus quam dignissim..